AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

This lens points to three standouts in retail, healthcare, and consumer goods. One pairs a modest yield with rapid hikes ...

The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...

ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...

Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...

With significant hedge fund interest and trending on Reddit, AbbVie Inc. (NYSE:ABBV) secures a spot on our list of the 10 ...

As in any month, September was eventful for AbbVie. In addition to news about its usual activities, it also scored big with ...

Rheumatoid Arthritis Treatment Market Boosted by Biologic Advances and Rising Disease Awareness Rheumatoid arthritis ...

President Donald Trump on Tuesday announced the creation of “TrumpRx,” a direct-to-consumer website where customers can buy drugs directly, as well as an agreement with pharmaceutical manufacturer ...

President Trump’s strategy to lower prescription drug prices will be put to the test as drugmakers must now commit to the terms of his “Most Favored Nation” pricing plan or face unspecified actions ...